Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from thyroid eye disease (TED). The company's primary product candidate, VRDN-001, is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) that holds promise for treating TED, a rare and debilitating condition.
Viridian Therapeutics leverages cutting-edge science and a deep understanding of disease biology to advance its therapeutic candidates. Their lead candidate, VRDN-001, is aimed at mitigating the symptoms of TED, which include inflammation, pain, and vision impairment. By targeting IGF-1R, VRDN-001 has the potential to offer a novel treatment option for patients who currently have limited choices.
The company’s commitment to scientific excellence is reflected in its rigorous clinical trials and strategic partnerships. Viridian collaborates with leading academic institutions and industry partners to enhance the development and potential commercialization of its therapies. These collaborations provide valuable resources and expertise, helping to accelerate the progress of their drug candidates.
In terms of financial health, Viridian Therapeutics is well-positioned with sufficient funding to advance its clinical programs. The company continuously explores opportunities to bolster its financial stability through strategic partnerships and potential equity financing. Viridian's prudent financial management ensures that it can sustain its operations and continue its mission to bring transformative therapies to patients in need.
Viridian's focus on thyroid eye disease addresses a significant unmet medical need. The company aims to develop treatments that improve the quality of life for patients suffering from this challenging condition. By pursuing innovative approaches and maintaining a patient-centric mindset, Viridian is making meaningful strides in the field of biopharmaceuticals.
Stay updated with the latest news and developments from Viridian Therapeutics as they progress in their mission to deliver groundbreaking therapies for underserved patient populations.
Viridian Therapeutics (Nasdaq: VRDN) announced that Jonathan Violin, Ph.D., and Barrett Katz, M.D., will participate in a panel presentation at the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021. The panel, titled TED Talk – State of Play in Thyroid Eye Disease, is scheduled for 1:45 p.m. ET. Webcast details can be found on the company’s website, and a replay will be available for 90 days after the live event. Viridian's lead program, VRDN-001, targets thyroid eye disease, an autoimmune condition affecting vision and causing significant patient discomfort.
Viridian Therapeutics (Nasdaq: VRDN) has appointed Kristian Humer as the new Chief Financial Officer and Chief Business Officer. Humer, with over 20 years of finance experience, will enhance the leadership team as they advance their investigational therapies pipeline, particularly focusing on Thyroid Eye Disease. An inducement grant of 360,000 shares will be awarded to Humer, vesting over four years. This strategic appointment aims to strengthen the company’s growth trajectory and address significant unmet medical needs in serious diseases.
Viridian Therapeutics (Nasdaq: VRDN) announced the appointment of Jennifer Moses, CPA, to its Board of Directors and as Chair of the Audit Committee. This strategic move aims to leverage her extensive financial and biotechnological expertise to support the company's clinical development initiatives for VRDN-001 and VRDN-002. CEO Jonathan Violin highlighted the importance of her leadership in enhancing financial oversight and advancing the company's commitment to providing new treatment options for patients suffering from Thyroid Eye Disease.
Viridian Therapeutics (Nasdaq: VRDN) announced an option grant to purchase 180,000 shares of common stock as an inducement for a new employee. This Inducement Grant, approved by a majority of the independent directors, is outside the company’s equity incentive plan but adheres to its terms. The exercise price is set at $17.20, matching the stock's closing price on July 6, 2021. The shares will vest over four years, with 25% vesting on the first anniversary, followed by monthly vesting. Viridian focuses on developing treatments for serious diseases, including TED, using monoclonal antibodies.
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on innovative treatments for serious diseases, announced that its CEO, Jonathan Violin, Ph.D., will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 14, 2021, at 9:00 a.m. ET. The event will be held virtually, and the presentation can be accessed through Viridian's website. The company is known for its monoclonal antibody program, VRDN-001, targeting Thyroid Eye Disease (TED), which causes significant discomfort and potential blindness.
Viridian Therapeutics (Nasdaq: VRDN) announced that Jonathan Violin, Ph.D., its CEO, will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 17, 2021, at 2:30 p.m. ET. This virtual event will focus on the company’s advancements in biopharmaceuticals for serious diseases. Interested parties can access the webcast on Viridian's website, with a replay available for 90 days post-event. Viridian is developing VRDN-001, targeting the debilitating autoimmune disease TED, which can lead to vision impairment.
Viridian Therapeutics (Nasdaq: VRDN) announced that Jonathan Violin, Ph.D., its President and CEO, will present a company overview at the Oppenheimer Rare & Orphan Disease Summit on May 21 at 9:05 a.m. ET. He will also participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1 at 11:30 a.m. ET. Both events will be accessible via webcasts on Viridian's website, with replays available for 90 days post-event. Viridian focuses on developing treatments for serious diseases, notably its anti-IGF-1R monoclonal antibody, VRDN-001, targeting Thyroid Eye Disease.
Viridian Therapeutics reported significant milestones in its thyroid eye disease (TED) programs VRDN-001 and VRDN-002. Both candidates are on track for IND filings in Q4 2021, with VRDN-001 showing promising preclinical data. As of March 31, 2021, the company had $117 million in cash, sufficient to fund operations into 2024. R&D expenses rose to $13.8 million due to advancing lead programs, while net losses increased to $18.5 million compared to last year.
Viridian Therapeutics (NASDAQ: VRDN) announced its financial results for Q4 and 2020, highlighting a significant cash position of $127.6 million, sufficient to fund operations into 2023. The company's revenue declined to $1.1 million for the year, primarily due to reduced activities related to legacy assets. Key developments include the advancement of lead programs VRDN-001 and VRDN-002, with IND filings expected by the end of 2021. Following the October 2020 merger, Viridian appointed a new leadership team, aiming to expand its pipeline and R&D for Thyroid Eye Disease (TED).
Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced a conference call and webcast on March 25, 2021, at 4:30 p.m. ET. The call will cover a corporate update and the results for Q4 and the full year 2020. Interested participants can join by calling 877-407-0789 domestically or 201-689-8562 internationally, using Conference ID 13717079. The live webcast is accessible via their Investor Relations website.
Viridian focuses on developing treatments for serious diseases, notably VRDN-001, an anti-IGF-1R monoclonal antibody for thyroid eye disease.
FAQ
What is the current stock price of Viridian Therapeutics (VRDN)?
What is the market cap of Viridian Therapeutics (VRDN)?
What does Viridian Therapeutics, Inc. do?
What is VRDN-001?
What condition does Viridian Therapeutics aim to treat?
How does VRDN-001 work?
Who are Viridian Therapeutics' partners?
What is the financial condition of Viridian Therapeutics?
Why is thyroid eye disease a focus for Viridian Therapeutics?
How can I stay updated on Viridian Therapeutics' progress?
Where is Viridian Therapeutics listed?
What makes Viridian Therapeutics' approach unique?
